Welcome to our dedicated page for ANAPTYSBIO SEC filings (Ticker: ANABV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ANAPTYSBIO's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ANAPTYSBIO's regulatory disclosures and financial reporting.
AnaptysBio, Inc. completed the spin-off of its former biopharma operations into First Tracks Biotherapeutics, creating a focused royalty management company. Shareholders received one share of First Tracks common stock for every one share of AnaptysBio common stock held on the April 6, 2026 record date. First Tracks now trades on Nasdaq under “TRAX,” while AnaptysBio continues under “ANAB.”
Post-spin, AnaptysBio retains the royalty management business, exclusively overseeing financial collaborations for Jemperli with GSK and imsidolimab with Vanda. Management highlights a virtual model with limited staff, minimal operating expenses and a targeted greater than 95% EBIT margin. The parties entered into a detailed Separation and Distribution Agreement and a Transition Services Agreement governing asset and liability allocations, shared IP, tax matters and up to two years of transition services. The spin-off also triggered board resignations and executive transitions, including the Chief Medical Officer moving to First Tracks and the CEO serving AnaptysBio via a consulting agreement.
AnaptysBio, Inc. completed the spin-off of its former biopharma operations into First Tracks Biotherapeutics, creating a focused royalty management company. Shareholders received one share of First Tracks common stock for every one share of AnaptysBio common stock held on the April 6, 2026 record date. First Tracks now trades on Nasdaq under “TRAX,” while AnaptysBio continues under “ANAB.”
Post-spin, AnaptysBio retains the royalty management business, exclusively overseeing financial collaborations for Jemperli with GSK and imsidolimab with Vanda. Management highlights a virtual model with limited staff, minimal operating expenses and a targeted greater than 95% EBIT margin. The parties entered into a detailed Separation and Distribution Agreement and a Transition Services Agreement governing asset and liability allocations, shared IP, tax matters and up to two years of transition services. The spin-off also triggered board resignations and executive transitions, including the Chief Medical Officer moving to First Tracks and the CEO serving AnaptysBio via a consulting agreement.